[1] |
Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell [J]. Nat Med,1997,3(7):730-737.
|
[2] |
Al-Hajj M, Wicha MS, Benito-Hernandez A, et al.Prospective identification of tumorigenic breast cancer cells [J]. Proc Natl Acad Sci USA. 2003;100(7):3983-8.
|
[3] |
Wright MH, Calcagno AM, Salcido CD, et al. Brca1 breast tumors contain distinct CD44+/CD24-and CD133+ cells with cancer stem cell characteristics[J]. Breast Cancer Res,2008,10(10):1186-1196.
|
[4] |
Al-Ejeh F, Smart CE, Morrison BJ, et al. Breast cancer stem cells: treatment resistance and therapeutic opportunities[J]. Carcinogenesis,2011,32(5):650-658.
|
[5] |
Giatromanolaki A, Sivridis E, Fiska A, el al. The CD44+/CD24- phenotype relates to “triple-negative” state and unfavorable prognosis in breast cancer patients [J]. Med Oncol,2011,28(3):745-752.
|
[6] |
Sheridan C, Kishimoto H, Fuchs RK, et al. CD44+/CD24-breast cancer cells exhibit enhanced invasive properties an early step necessary for metastasis [J]. Breast Cancer Res,2006,8(5):59-72.
|
[7] |
Aulmann S, Waldburger N, Penzel R, et al. Reduction of CD44+/CD24- breast cancer cells by conventional cytotoxic chemotherapy [J]. Human Pathol,2010,41(4):574-581
|
[8] |
Lin WM, Karsten U, Goletz S, et al. Expression of CD176 (Thomsen-Friedenreich antigen) on lung, breast and liver cancer-initiating cells [J]. Int J Exp Path,2011,92(2):97-105.
|
[9] |
Charafe-Jauffreta E, Monvillea F, Ginestier C, et al. Cancer stem cells in breast: current opinion and future challenges[J]. Pathobiology,2008,75(2):75-84.
|
[10] |
Ponti D, Costa A, Zaffaroni N, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties [J]. Cancer Res,2005,65(13):5506-5511.
|
[11] |
Dey D, Saxena M, Paranjape AN, et al. Phenotypic and functional characterization of human mammary stem/progenitor cells in long term culture [J]. PLoS ONE,2009,4(4):5329-5341.
|
[12] |
Sophos NA, Vasiliou V. Aldehyde dehydrogenase gene superfamily: the 2002 update[J]. Chem Biol Interact,2003,143(144):5-22.
|
[13] |
Marcato P, Dean CA, Pan D, et al. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis[J]. Stem Cells,2011,29(1):32-45.
|
[14] |
Neumeister V, Rimm D. Is ALDH1 a good method for definition of breast cancer stem cells? [J] Breast Cancer Res Treat,2010,123(1):109-111.
|
[15] |
Greenburg G, Hay ED. Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells[J]. J Cell Biol,1982,95(1):333-339.
|
[16] |
Morel AP, Lievre M, Thomas C, et al. Generation of breast cancer stem cells through epithelial-mesenchymal transition[J]. PLoS ONE,2008,3(8):e2888.
|
[17] |
Ansieau S, Bastid J, Doreau A, et al. Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence[J]. Cancer Cell,2008,14(1):79-89.
|
[18] |
Cheng GZ, Chan J, Wang Q, et al. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel[J]. Cancer Res,2007,67(5):1979-1987.
|
[19] |
Boulanger CA, Mack DL, Booth BW, Interaction with the mammary microenvironment redirects spermatogenic cell fate in vivo[J]. Proc Natl Acad Sci USA,2007,104(10):3871-3876.
|
[20] |
Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis[J]. Nature,2007:449(7162):557-563.
|
[21] |
Rosen JM, Jordan CT. The increasing complexity of the cancer stem cell paradigm[J]. Science, 2009, 324(5935):1670-1673.
|
[22] |
Liu S, Ginestier C, Ou SJ, et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks [J]. Cancer Res,2011,71(2):614-624.
|
[23] |
Cipak A, Mrakovcic L, Ciz M, et al. Growth suppression of human breast carcinoma stem cells by lipid peroxidation product 4-hydroxy-2-nonenal and hydroxyl radical-modified collagen [J]. Acta Biochim Pol,2010,57(2):165-171.
|
[24] |
Abraham BK, Fritz P, McClellan M, et al. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis [J].Clin Cancer Res,2005,11(3):1154-1159.
|
[25] |
Li RJ, Ying X, Zhang Y, et al. All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells[J]. J Control Release,2011,149(3):281-291.
|
[26] |
Takehara M, Hoshino T, Namba T, et al. Acetaminophen-induced differentiation of human breast cancer stem cells and inhibition of tumor xenograft growth in mice[J]. Biochem Pharmacol,2011,81(9):1124-1135.
|
[27] |
Ting AH, McGarvey KM, Baylin SB. The cancer epigenome—components and functional correlates. Genes Dev, 2006,20(23):3215-3231.
|
[28] |
DiMeo TA, Anderson K, Phadke P, et al. A novel lung metastasis signature links Wnt signaling with cancer cell selfrenewal and epithelial-mesenchymal transition in basal-like breast cancer[J]. Cancer Res,2009,69(13):5364-5373.
|
[29] |
Hirose H, Ishii H, Mimori K, et al. Notch pathway as candidate therapeutic target in Her2/Neu/ErbB2 receptor-negative breast tumors[J]. Oncol Rep,2010,23(1):35-43.
|
[30] |
Mine T, Matsueda S, Li YF, et al. Breast cancer cells expressing stem cell markers CD44+ CD24low are eliminated by Numb-1 peptide-activated T cells[J]. Cancer Immunol Immunother,2009,58(8):1185-1194.
|
[31] |
Ao A, Morrison BJ, Wang H, et al. Response of estrogen receptor-positive breast cancer tumorspheres to antiestrogen treatments[J]. PLoS ONE,2011,6(4):188-199.
|
[32] |
Guo J, Zhou J, Ying X, et al. Effects of stealth liposomal daunorubicin plus tamoxifen on the breast cancer and cancer stem cells[J]. J Pharm Pharmaceut Sci,2010,13(2):136-151.
|